Elevar Therapeutics (previously known as LSK BioPharma) is a pharmaceutical company. It specializes in the clinical development of therapies for unmet medical needs in cancer. It develops two proprietary drug candidates: rivoceranib (Apatinib), a VEGFR-2 inhibitor, which dealing with a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.
|HQ||South San Francisco, CA, US||Map|
|Employees (est.) (Sept 2021)||46||(+5%)|
Elevar Therapeutics total Funding
Elevar Therapeutics latest funding size
Time since last funding
|3 years ago|
When was Elevar Therapeutics founded?
Elevar Therapeutics was founded in 2005.
Who are Elevar Therapeutics key executives?
Elevar Therapeutics's key executives are Kate McKinley, Soo Whan Choi and Yang Gon Jin.
How many employees does Elevar Therapeutics have?
Elevar Therapeutics has 46 employees.
Who are Elevar Therapeutics competitors?
Competitors of Elevar Therapeutics include DAVA Oncology, OBI Pharma and Providence Therapeutics.
Where is Elevar Therapeutics headquarters?
Elevar Therapeutics headquarters is located at 400 Oyster Point Blvd #214, South San Francisco.
Where are Elevar Therapeutics offices?
Elevar Therapeutics has offices in South San Francisco, Salt Lake City and Dublin.
How many offices does Elevar Therapeutics have?
Elevar Therapeutics has 4 offices.
Receive alerts for 300+ data fields across thousands of companies